Literature DB >> 15701833

Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma.

Eduard Ryschich1, Tanja Nötzel, Ulf Hinz, Frank Autschbach, James Ferguson, Ioan Simon, Jürgen Weitz, Boris Fröhlich, Ernst Klar, Markus W Büchler, Jan Schmidt.   

Abstract

PURPOSE: Cell surface HLA class I molecules present peptides derived from human cellular proteins to T cells. In the present study, we investigated the expression of HLA class I in human pancreatic carcinoma. EXPERIMENTAL
DESIGN: The expression of HLA class I antigen and the extent of tumor infiltration by T cells were investigated in 46 primary tumors and in 14 metastases of pancreatic cancer by standard immunohistochemistry.
RESULTS: The locus-specific expression of HLA I was reduced in 61% of primary tumors and in 93% of metastases. The total loss of this molecule complex was detected in 6% of primary tumors and in 43% of metastases. Pancreatic carcinoma and peritumoral tissue showed a significantly higher infiltration by CD3+, CD4+, and CD8+ T-cells compared with the tumor-distant pancreatic tissue. The negative expression of HLA class I was uniformly accompanied by a low density of tumor-infiltrating cytotoxic T-cells whereas the HLA class I-positive tumors were characterized by a substantial lymphocyte accumulation. However, the infiltration by cytotoxic T-cells was not correlated with the density of tumor cells. Patients with a high accumulation of cytotoxic cells showed a longer median survival.
CONCLUSIONS: Pancreatic carcinoma frequently induces a cellular immune response that results in intratumoral and peritumoral T-cell infiltration. The expression of HLA class I is frequently lost in pancreatic carcinoma, which represents an effective mechanism to escape the tumor infiltration by cytotoxic T-cells. However, the infiltration by cytotoxic cells represents a favorable prognostic sign in pancreatic cancer patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15701833

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  70 in total

1.  Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells.

Authors:  Kaoru Nagato; Shinichiro Motohashi; Fumihiro Ishibashi; Kohsuke Okita; Kazuki Yamasaki; Yasumitsu Moriya; Hidehisa Hoshino; Shigetoshi Yoshida; Hideki Hanaoka; Shin-Ichiro Fujii; Masaru Taniguchi; Ichiro Yoshino; Toshinori Nakayama
Journal:  J Clin Immunol       Date:  2012-04-26       Impact factor: 8.317

2.  Immunosuppressive CD14+HLA-DRlo/neg monocytes are elevated in pancreatic cancer and "primed" by tumor-derived exosomes.

Authors:  Naureen Javeed; Michael P Gustafson; Shamit K Dutta; Yi Lin; William R Bamlet; Ann L Oberg; Gloria M Petersen; Suresh T Chari; Allan B Dietz; Debabrata Mukhopadhyay
Journal:  Oncoimmunology       Date:  2016-11-02       Impact factor: 8.110

Review 3.  The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Authors:  Federico Nichetti; Antonio Marra; Francesca Corti; Alessandro Guidi; Alessandra Raimondi; Natalie Prinzi; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

Review 4.  Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.

Authors:  Paul Mayor; Kristen Starbuck; Emese Zsiros
Journal:  Gynecol Oncol       Date:  2018-05-24       Impact factor: 5.482

Review 5.  Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.

Authors:  Vishal Jindal; Ena Arora; Muhammad Masab; Sorab Gupta
Journal:  Med Oncol       Date:  2018-05-04       Impact factor: 3.064

6.  HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15.

Authors:  María A Garrido; Teresa Rodriguez; Svitlana Zinchenko; Isabel Maleno; Francisco Ruiz-Cabello; Ángel Concha; Nicolás Olea; Federico Garrido; Natalia Aptsiauri
Journal:  Immunogenetics       Date:  2018-08-25       Impact factor: 2.846

7.  Pancreatic Tumor Microenvironment.

Authors:  Kai Wang; Hong He
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 8.  Process of hepatic metastasis from pancreatic cancer: biology with clinical significance.

Authors:  Haojun Shi; Ji Li; Deliang Fu
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-07       Impact factor: 4.553

9.  The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines.

Authors:  Kenneth W Hance; Connie J Rogers; David A Zaharoff; Daniel Canter; Jeffrey Schlom; John W Greiner
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

Review 10.  Complex role for the immune system in initiation and progression of pancreatic cancer.

Authors:  Kristin S Inman; Amanda A Francis; Nicole R Murray
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.